Search
01/05/2022
Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma
Garcia-Melendo, C, Morales-Munera, CE, Dalmau, J, Cubiro, X, Lopez-Sanchez, C, Mozos, A, Yelamos, O. Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma. Dermatologic Therapy. 2022; 35(5)DOI:10.1111/dth.15388. PMID:35174945. IF:3.600(Q1/3D).
03/04/2022
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
Reich, K, Conrad, C, Kristensen, LE, Smith, SD, Puig, L, Rich, P, Sapin, C, Holzkaemper, T, Koppelhus, U, Schuster, C. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(3)DOI:10.1080/09546634.2021.1892024. PMID:33641593. IF:2.900(Q2/4D).
01/04/2022
Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome
Iznardo, H, Bredrup, C, Bernal, S, Gladkauskas, T, Mascaro, JM, Roe, E, Baselga, E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4)DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2.000(Q3/8D).
01/02/2022
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
del Alcazar, E, Lopez-Ferrer, A, Martinez-Domenech, A, Ruiz-Villaverde, R, Llamas-Velasco, MD, Rocamora, V, Julia, M, Notario, J, Fernandez-Freire, LR, Sahuquillo-Torralba, A, Vidal, D, Rivera, R, Carretero, G, Mateu, A, de la Cueva, P, Carrascosa, JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy. 2022; 35(2)DOI:10.1111/dth.15231. PMID:34820971. IF:3.600(Q1/3D).
01/02/2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
Thaci, D, Strober, B, Gordon, KB, Foley, P, Gooderham, M, Morita, A, Papp, KA, Puig, L, Menter, MA, Colombo, MJ, Elbez, Y, Kisa, RM, Ye, JN, Napoli, AA, Wei, L, Banerjee, S, Merola, JF, Gottlieb, AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 2022; 12(2)DOI:10.1007/s13555-021-00649-y. PMID:35025062. IF:3.400(Q2/3D).
01/01/2022
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
Armstrong, AW, Soliman, AM, Betts, KA, Wang, Y, Gao, YW, Stakias, V, Puig, L. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy. 2022; 12(1)DOI:10.1007/s13555-021-00647-0. PMID:34862951. IF:3.400(Q2/3D).
01/01/2022
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis
Krueger, J, Puig, L, Thaci, D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1)DOI:10.1007/s40257-021-00658-9. PMID:35061230. IF:7.300(Q1/1D).
01/01/2022
Pathophysiology of Generalized Pustular Psoriasis
Marrakchi, S, Puig, L. Pathophysiology of Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1)DOI:10.1007/s40257-021-00655-y. PMID:35061228. IF:7.300(Q1/1D).